Literature DB >> 30977913

Percutaneous management of malignant biliary disease.

Ahsun Riaz1, John P Pinkard1, Riad Salem1,2,3, Robert J Lewandowski1,3.   

Abstract

Percutaneous biliary interventions have established their role in the management of benign and malignant biliary disease. There are limited data comparing procedures performed by gastroenterologists and interventional radiologists in managing malignant biliary obstruction. Endoscopic procedures performed by gastroenterologists are not completely benign with reported complications ranging from 2% to 15%. It is important that gastroenterologists and interventional radiologists collaborate to form algorithms for management of malignant biliary obstruction which provide safe and efficacious care to these patients.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  biliary intervention; biliary stenting; interventional radiology; percutaneous transhepatic cholangiography

Mesh:

Year:  2019        PMID: 30977913     DOI: 10.1002/jso.25471

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

Review 1.  Percutaneous Biliary Endoscopy.

Authors:  Adam Khayat; Mamdouh Khayat; Michael Cline; Ahsun Riaz
Journal:  Semin Intervent Radiol       Date:  2021-08-10       Impact factor: 1.780

Review 2.  Role of Interventional Radiology in the Management of Acute Cholangitis.

Authors:  Pouya Entezari; Jonathan A Aguiar; Riad Salem; Ahsun Riaz
Journal:  Semin Intervent Radiol       Date:  2021-08-10       Impact factor: 1.780

Review 3.  Future Directions of Percutaneous Biliary Interventions.

Authors:  Ahsun Riaz; Riad Salem
Journal:  Semin Intervent Radiol       Date:  2021-08-10       Impact factor: 1.780

4.  Survival prediction for patients with malignant biliary obstruction caused by pancreatic cancer undergoing biliary drainage: the COMBO-PaS model.

Authors:  Hai-Feng Zhou; Jia-Lei Wang; Wei Yang; Chun Zhou; Yan Shen; Ling-Ling Wu; Zhong-Ling Pei; Wei-Zhong Zhou; Sheng Liu; Hai-Bin Shi
Journal:  Surg Endosc       Date:  2022-10-19       Impact factor: 3.453

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.